LongevityNext / Trials
Source-reviewed evidence, findings and limitations. Research intelligence, not treatment recommendations.
34 eligible records
Evidence reviewed
COSMOS: COSMOS ancillary studies support a small multivitamin cognitive-performance signal, not demonstrated dementia prevention or three independent trial replications.
Boundary: Small score shifts or age-equivalent calibrations are not demonstrated rejuvenation.
Evidence reviewed
VITAL fracture ancillary: Vitamin D3 did not reduce incident fractures in VITAL's broadly recruited, non-deficiency-selected population.
Boundary: These trials do not answer treatment of established deficiency, osteomalacia or every high-risk skeletal indication.
Evidence reviewed
VITAL: VITAL's marine omega-3 supplement did not significantly reduce its primary major cardiovascular endpoint in general primary prevention.
Boundary: Cross-trial differences cannot identify whether formulation, comparator or risk caused the different results.
Evidence reviewed
Creatine postmenopausal bone 2-year trial: The larger two-year creatine-plus-training trial did not confirm the smaller study's femoral-neck bone-density benefit.
Boundary: Fracture prevention and universal creatine ineffectiveness are both unestablished.
Evidence reviewed
NMN prediabetic-women trial: NMN improved a skeletal-muscle insulin-sensitivity readout in a small trial of prediabetic postmenopausal women, without establishing diabetes prevention or generalized metabolic rejuvenation.
Boundary: No diabetes-prevention, sarcopenia-prevention or aging-reversal claim is supported.
Evidence reviewed
SmartAge: The larger SmartAge trial did not confirm a memory benefit of spermidine-rich extract despite the earlier small pilot signal.
Boundary: The 0.9-mg extract regimen cannot be generalized to all spermidine doses or formulations.
Evidence reviewed
UA older-adult endurance trial: Urolithin A did not significantly improve the older-adult trial's primary walking or maximal ATP endpoints; secondary muscle-endurance signals remain exploratory context.
Boundary: Mitochondrial target engagement is not proof of frailty prevention or longer life.
Evidence reviewed
RTB101's phase 2b respiratory-infection signal followed failure of the first fixed-sequence test.
Boundary: The second prespecified analysis was multiplicity-unadjusted, not confirmatory success.
Evidence reviewed
Generation 100 compared interval or continuous exercise with active guideline controls over five years.
Boundary: Combined exercise did not demonstrate a mortality advantage; null is not equivalence.
Evidence reviewed
LIFE reduced major mobility disability with walking, resistance and flexibility training versus health education in vulnerable older adults.
Boundary: A function-limited volunteer population; this was not a mortality trial.
Evidence reviewed
CALERIE calorie restriction improved several risk factors while reducing bone density over two years.
Boundary: Risk-factor changes are not clinical-event benefit; bone loss is not proven fracture harm.
Evidence reviewed
Weekly sirolimus plus home exercise did not significantly improve the primary chair-stand outcome in RAPA-EX-01.
Boundary: Small, short trial; sensitivity findings cannot replace the primary analysis.